Harnessing engineered antibodies of the IgE class to combat malignancy: Initial assessment of Fce{open}RI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity

Clinical and Experimental Allergy

Volumn 41, Issue 10, 2011, Pages 1400-1413

  Rudman, S M ^a,b   Josephs, D H ^a,b   Cambrook, H ^a   Karagiannis, P ^a   Gilbert, A E ^a   Dodev, T ^c,d   Hunt, J ^c,d   Koers, A ^e   Montes, A ^a   Taams, L ^d   Canevari, S ^f   Figini, M ^f   Blower, P J ^e   Beavil, A J ^c,d   Nicodemus, C F ^g   Corrigan, C ^d   Kaye, S B ^h   Nestle, F O ^a   Gould, H J ^c,d   Spicer, J F ^b   Karagiannis, S N ^a   more..

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Advanced Immune Therapeutics Inc   (United States)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anaphylaxis; Basophil; Cancer therapy; CD63; Degranulation; FR ; Tumour antigen specific IgE; Type I hypersensitivity

Indexed keywords

CD63 ANTIGEN; FC EPSILON RI; FC RECEPTOR; FOLATE RECEPTOR 1; IMMUNOGLOBULIN E ANTIBODY; MOV18 IMMUNOGLOBULIN E ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY ENGINEERING; ARTICLE; BASOPHIL; CANCER PATIENT; CELL ACTIVATION; CONTROLLED STUDY; DEGRANULATION; EFFECTOR CELL; EX VIVO STUDY; FEMALE; GENETIC TRANSFECTION; GRANULE CELL; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; LEUKEMIA CELL LINE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; ANTIGENS, CD63; ANTIGENS, NEOPLASM; BASOPHILS; CARCINOMA; CELL DEGRANULATION; CELL LINE, TUMOR; FEMALE; FOLATE RECEPTOR 1; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; OVARIAN NEOPLASMS; PROTEIN ENGINEERING; RATS; RECEPTORS, IGE;

EID: 80052966648     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03770.x     Document Type: Article

References (57)

1. Weiner LM, Surana R, Wang S.Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27.
2. Karagiannis SN, Wang Q, East Net al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003; 33:1030-40.
3. Karagiannis SN, Bracher MG, Hunt Jet al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179:2832-43.
4. Karagiannis SN, Bracher MG, Beavil RLet al. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 2008; 57:247-63.
5. Karagiannis SN, Nestle FO, Gould HJ.IgE interacts with potent effector cells against tumours: ADCC and ADCP. In: Penichet ML, Jensen-Jarolim E, eds. Cancer and IgE: introducing the concept of allergooncology. Berlin: Springer, 2010; 185-213.
6. Karagiannis P, Singer J, Hunt Jet al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009; 58:915-30.
7. Gould HJ, Mackay GA, Karagiannis SNet al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999; 29:3527-37.
8. Gould HJ, Sutton BJ, Beavil AJet al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003; 21:579-628.
9. Gould HJ, Sutton BJ.IgE in allergy and asthma today. Nat Rev Immunol 2008; 8:205-17.
10. Jensen-Jarolim E, Achatz G, Turner MCet al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008; 63:1255-66.
11. Nigro EA, Brini AT, Soprana Eet al. Antitumor IgE adjuvanticity: key role of Fc epsilon RI. J Immunol 2009; 183:4530-6.
12. Teng MW, Kershaw MH, Jackson JT, Smyth MJ, Darcy PK.Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy. Hum Gene Ther 2006; 17:1134-43.
13. Riemer AB, Untersmayr E, Knittelfelder Ret al. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res 2007; 67:3406-11.
14. Reali E, Greiner JW, Corti Aet al. IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res 2001; 61:5517-22.
15. White AJ, Coleman RL, Armstrong DK, Glenn D.et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study. J Clin Oncol 2010; 28(Suppl.); abstract 5001.
16. Molthoff CF, Prinssen HM, Kenemans P, van Hof AC, den Hollander W, Verheijen RH.Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 1997; 80:2712-20.
17. Macor P, Mezzanzanica D, Cossetti Cet al. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 2006; 66:3876-83.
18. Toffoli G, Russo A, Gallo Aet al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998; 79:121-6.
19. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA.Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992; 52:6708-11.
20. Amini RM, Aaltonen K, Nevanlinna Het al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 2007; 7:165.
21. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST.Mast cells and cutaneous malignancies. Mod Pathol 2006; 19:149-59.
22. Wasiuk A, de Vries VC, Nowak EC, Noelle RJ.Mast cells in allergy and tumour disease. In: Penichet ML, Jensen-Jarolim E, eds. Cancer and IgE: introducing the concept of allergooncology. Berlin: Springer, 2010; 137-58.
23. Christensen LH, Holm J, Lund G, Riise E, Lund K.Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. J Allergy Clin Immunol 2008; 122:298-304.
24. Valenta R, Ferreira F, Focke-Tejkl Met al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-41.
25. Figini M, Martin F, Ferri Ret al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother 2009; 58:531-46.
26. Luhrs CA, Pitiranggon P, da Costa Met al. Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation. Proc Natl Acad Sci USA 1987; 84:6546-9.
27. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF.Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009; 27:418-25.
28. Dibbern DA Jr, Palmer GW, Williams PB, Bock SA, Dreskin SC.RBL cells expressing human Fc epsilon RI are a sensitive tool for exploring functional IgE-allergen interactions: studies with sera from peanut-sensitive patients. J Immunol Methods 2003; 274:37-45.
29. Wiegand TW, Williams PB, Dreskin SC, Jouvin MH, Kinet JP, Tasset D.High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J Immunol 1996; 157:221-30.
30. Karagiannis SN, Warrack JK, Jennings KHet al. Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells. Immunology 2001; 103:319-31.
31. De Week AL, Sanz ML, Gamboa PMet al. Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. II. Technical issues. J Investig Allergol Clin Immunol 2008; 18:143-55.
32. Boumiza R, Debard AL, Monneret G.The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy 2005; 3:9.
33. Naal RM, Holowka EP, Baird B, Holowka D.Antigen-stimulated trafficking from the recycling compartment to the plasma membrane in RBL mast cells. Traffic 2003; 4:190-200.
34. Lisboa FA, Peng Z, Combs CA, Beaven MA.Phospholipase d promotes lipid microdomain-associated signaling events in mast cells. J Immunol 2009; 183:5104-12.
35. Bodinier M, Brossard C, Triballeau Set al. Evaluation of an in vitro mast cell degranulation test in the context of food allergy to wheat. Int Arch Allergy Immunol 2008; 146:307-20.
36. Nakamura R, Uchida Y, Higuchi M, Tsuge I, Urisu A, Teshima R.A convenient and sensitive allergy test: IgE crosslinking-induced luciferase expression in cultured mast cells. Allergy 2010; 65:1266-73.
37. Knol EF. Requirements for effective IgE cross-linking on mast cells and basophils. Mol Nutr Food Res 2006; 50:620-4.
38. van Zanten-Przybysz I, Molthoff C, Gebbinck JKet al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol 2002; 128:484-92.
39. Basal E, Eghbali-Fatourechi GZ, Kalli KRet al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 2009; 4:e6292.
40. Ntouroupi TG, Ashraf SQ, McGregor SBet al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008; 99:789-95.
41. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML.Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009; 112:185-91.
42. He W, Kularatne SA, Kalli KRet al. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer 2008; 123:1968-73.
43. He W, Wang H, Hartmann LC, Cheng JX, Low PS.In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci USA 2007; 104:11760-5.
44. Poveda A, Kaye SB, McCoramck RT, Wang Set al. Circulating tumour cells in a study of relapsed/recurrent advanced ovarian cancer: an exploratory analysis in the ova-301 phase III study of pegylated liposimal doxorubicin (PLD) compared with trabectadin and PLD. J Clin Oncol 2009; 27: abstract 5551.
45. Kindelberger DDK, Kantoff E, Atkinson Tet al. Predictive value of circulating tumour cells for response to therapy in women with recurrent epithelial ovarian cancer. J Clin Oncol 2010; 28: abstract 5111.
46. Metzelaar MJ, Wijngaard PL, Peters PJ, Sixma JJ, Nieuwenhuis HK, Clevers HC.CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 1991; 266:3239-45.
47. Weisberg E, Manley PW, Breitenstein Wet al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7:129-41.
48. Porterfield HS, Murray KS, Schlichting DGet al. Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants. Clin Exp Allergy 2009; 39:1099-108.
49. Blanc F, Adel-Patient K, Drumare MF, Paty E, Wal JM, Bernard H.Capacity of purified peanut allergens to induce degranulation in a functional in vitro assay: Ara h 2 and Ara h 6 are the most efficient elicitors. Clin Exp Allergy 2009; 39:1277-85.
50. Lennon S, Barton C, Banken Let al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009; 27:1685-93.
51. Molloy AM, Quadros EV, Sequeira JMet al. Lack of association between folate-receptor autoantibodies and neural-tube defects. N Engl J Med 2009; 361:152-60.
52. Lin RY, Schwartz LB, Curry Aet al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000; 106:65-71.
53. Simons FE, Frew AJ, Ansotegui IJet al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2-S24.
54. Elit L, Konner JA, Armstrong DK, Buck M.et al. A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. J Clin Oncol 2010; 28: TPS255.
55. Konner JA, Bell-McGuinn KM, Sabbatini Pet al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010; 16:5288-95.
56. Zacchetti A, Coliva A, Luison Eet al. (177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol 2009; 36:759-70.
57. van Zanten-Przybysz I, Molthoff CF, Roos JCet al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.. Int J Cancer 2001; 92:106-14.